“Neuroinflammation plays an important role in the pathophysiology of Alzheimer’s disease. The cannabinoid type 2 receptor (CB₂R) is an emerging target for neuroinflammation and therapeutics of Alzheimer’s disease. Here, we aim to assess the alterations in brain CB₂R levels and evaluate novel CB₂R imaging tracers in the arcAß mouse model of Alzheimer’s disease amyloidosis. Immunohistochemical staining for amyloid-ß deposits (6E10), microgliosis (anti-Iba1 and anti-CD68 antibodies), astrocytes (GFAP) and the anti-CB₂R antibody was performed on brain slices from 17-month-old arcAß mice. Autoradiography using the CB₂R imaging probes [¹⁸F]RoSMA-18-d6, [¹¹C]RSR-056, and [¹¹C]RS-028 and mRNA analysis were performed in brain tissue from arcAß and non-transgenic littermate (NTL) mice at 6, 17, and 24 months of age. Specific increased CB₂R immunofluorescence intensities on the increased number of GFAP-positive astrocytes and Iba1-positive microglia were detected in the hippocampus and cortex of 17-month-old arcAß mice compared to NTL mice. CB₂R immunofluorescence was higher in glial cells inside 6E10-positive amyloid-ß deposits than peri-plaque glial cells, which showed low background immunofluorescence in the hippocampus and cortex of 17-month-old arcAß mice. Ex vivo autoradiography showed that the specific binding of [¹⁸F]RoSMA-18-d6 and [¹¹C]RSR-056 was comparable in arcAß and NTL mice at 6, 17, and 24 months of age. The level of Cnr2 mRNA expression in the brain was not significantly different between arcAß and NTL mice at 6, 17, or 24 months of age. In conclusion, we demonstrated pronounced specific increases in microglial and astroglial CB₂R expression levels in a mouse model of AD-related cerebral amyloidosis, emphasizing CB₂R as a suitable target for imaging neuroinflammation.”

https://pubmed.ncbi.nlm.nih.gov/36248003/

https://www.frontiersin.org/articles/10.3389/fnagi.2022.1018610/full